BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27355512)

  • 1. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
    Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
    Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
    Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
    Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
    Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
    Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
    Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.
    John J; Loo A; Mazur S; Walsh TJ
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939
    [No Abstract]   [Full Text] [Related]  

  • 12. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.
    Tamura N; Okano A; Kuroda T; Niwa H; Kusano K; Matsuda Y; Fukuda K; Mita H; Nagata S
    Vet Ophthalmol; 2020 Jul; 23(4):640-647. PubMed ID: 32383526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
    Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
    Stott KE; Hope WW
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.
    Box H; Negri C; Livermore J; Whalley S; Johnson A; McEntee L; Alastruey-Izquierdo A; Meis JF; Thornton C; Hope W
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439967
    [No Abstract]   [Full Text] [Related]  

  • 19. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
    Marks DI; Liu Q; Slavin M
    Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
    Dolton MJ; McLachlan AJ
    Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.